Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial Adeona Pharmaceuticals, 9 Sep 2011 Accessed on 3 Jan 2012 from http://www.syntheticbiologics.com/index.php?s=43&item=90.
ChemIDplus Advanced United States National Library of Medicine Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp. Note: Compound name must be entered under "Substance Identification" and then "Names and Synonyms" selected to view synonyms.
Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. Soldan SS, Alvarez Retuerto A I, Sicotte NL, Voskuhl RR J Immunol. 2003 Dec 1; 171(11):6267-74. PMID: 14634144. Abstract
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research Adeona Pharmaceuticals, 11 Nov 2011 Accessed on 3 Jan 2012 from http://www.syntheticbiologics.com/index.php?s=43&item=99.
Estrogen treatment in multiple sclerosis. Gold SM, Voskuhl RR J Neurol Sci. 2009 Nov 15; 286(1-2):99-103. Epub 2009 Jun 18. PMID: 19539954. Abstract
Treatment of multiple sclerosis with the pregnancy hormone estriol. Sicotte NL, Liva SM, Klutch R, Pfeiffer P, Bouvier S, Odesa S, Wu JTC, Voskuhl RR Ann Neurol. 2002 Oct; 52(4):421-8. PMID: 12325070. Abstract
Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity. Papenfuss TL, Powell ND, McClain MA, Bedarf A, Singh A, Gienapp IE, Shawler T, Whitacre CC J Immunol. 2011 Mar 15; 186(6):3346-55. Epub 2011 Feb 11. PMID: 21317386. Abstract
Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T N Engl J Med. 1998 Jul 30; 339(5):285-91. PMID: 9682040. Abstract
Trimesta (Oral Estriol) Multiple Sclerosis Resource Center Accessed on 5 Jan 2012 from http://www.msrc.co.uk/index.cfm/fuseaction/show/pageid/1878.
Estriol Treatment in Multiple Sclerosis: Effect on Cognition ClinicalTrials.gov, 2 Nov 2011 Accessed on 3 Jan 2012 from http://clinicaltrials.gov/ct2/show/NCT01466114.
A Combination Trial of Copaxone plus Estriol in Relapsing Remitting Multiple Sclerosis ClinicalTrials.gov, 23 Jan 2012 Accessed on 20 Feb 2012 from http://clinicaltrials.gov/ct2/show/NCT00451204.
Trimesta in relapsing-remitting multiple sclerosis patients (Phase II) Accessed on 10 August 2012 from http://www.syntheticbiologics.com/index.php?s=68&item=77.
Editors' Pick Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease. Ziehn MO, Avedisian AA, Dervin SM, O'Dell TJ, Voskuhl RR Lab Invest. 2012 Aug; 92(8):1234-45. Epub 2012 Apr 23. PMID: 22525427. Abstract
Synthetic Biologics announces issuance of U.S. patent covering combination of estriol and Copaxone® for multiple sclerosis Synthetic Biologics, 4 Apr 2013 Accessed on 8 Apr 2013 from http://www.syntheticbiologics.com/2013-04-04-Synthetic-Biologics-Announces-Issuance-of-U-S-Patent-Covering-Combination-of-Estriol-and-Copaxone-for-Multiple-Sclerosis.
Synthetic Biologics Announces Issuance of U.S. Patent Adding Another Layer of Protection for the Use of Oral Estriol Candidate, Trimesta™, for Multiple Sclerosis Synthetic Biologics, 10 Mar 2014 Accessed on 11 Mar 2014 from http://www.syntheticbiologics.com/2014-03-10-Synthetic-Biologics-Announces-Issuance-of-U-S-Patent-Adding-Another-Layer-of-Protection-for-the-Use-of-Oral-Estriol-Candidate-Trimesta-for-Multiple-Sclerosis.
Synthetic Biologics Reports UCLA Announcement of Preliminary Positive Topline Efficacy and Safety Results from Investigator-Led Phase II Study of Trimesta™ for RRMS Synthetic Biologics, 29 Apr 2014 Accessed on 5 May 2014 from http://www.syntheticbiologics.com/2014-04-29-Synthetic-Biologics-Reports-UCLA-Announcement-of-Preliminary-Positive-Topline-Efficacy-and-Safety-Results-from-Investigator-Led-Phase-II-Study-of-Trimesta-for-Relapsing-Remitting-Multiple-Sclerosis.
Pregnancy level of estrogen attenuates experimental autoimmune encephalomyelitis in both ovariectomized and pregnant C57BL/6 mice through expansion of Treg and Th2 cells. Haghmorad D, Amini A A, Mahmoudi M B, Rastin M, Hosseini M, Mahmoudi M J Neuroimmunol. 2014 Oct 18; 277(1-2):85-95. PMID: 25457839. Abstract
Editors' Pick Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Voskuhl RR, Wang HJ, Wu JTC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, et al. Lancet Neurol. 2015 Nov 24. PMID: 26621682. Abstract
Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis Synthetic Biologics, 2 Feb 2016 Accessed on 9 Feb 2016 from http://www.syntheticbiologics.com/news-media/press-releases/detail/198/synthetic-biologics-reports-results-of-independent-third.